Explore 3 Stock Ideas & Industry Insights Download Free Report

News

ANI Pharmaceuticals (NASDAQ: ANIP): Cortrophin Gel Drives Record Quarterly Growth

ANI Pharmaceuticals is a diversified drugmaker headquartered in Princeton, New Jersey, operating across three segments: rare disease, generics and established brands. Its flagship product is Cortrophin Gel (repository corticotropin injection), a purified adrenocorticotropic hormone therapy used in conditions spanning rheumatology, neurology and ophthalmology. On …

Nitish Kishor | 10 September 2026

Avoca (AVOA): Why the Ticker's Identity and Listing Status Need Verifying

Efforts to confirm a listed operating company behind the AVOA ticker were inconclusive. Standard market-data pages for AVOA, as either a common stock or an exchange-traded fund, were not available, and a full-text search of U.S. Securities and Exchange Commission filings returned no operating …

Nitish Kishor | 10 September 2026

Tenaya Therapeutics (NASDAQ: TNYA): Gene Therapy Data for Inherited Heart Disease

Tenaya Therapeutics is a South San Francisco-based clinical-stage biotechnology company developing therapies for genetic and other forms of heart disease. Its lead gene-therapy programs are TN-201, aimed at MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, targeting PKP2-associated arrhythmogenic right ventricular cardiomyopathy. On August 5, 2026, Tenaya …

Nitish Kishor | 10 September 2026

Stryker Corporation (NYSE: SYK): Robotics and Implants Anchor a Medtech Giant

Stryker (SEC CIK 310764) is a diversifiedMedTechgiant organized around two broad segments: MedSurg and Neurotechnology, and Orthopaedics and Spine. Its portfolio spans surgical instruments, hospital equipment, neurovascular devices, trauma and joint-replacement implants, and - most visibly - the Mako robotic-arm platform used in orthopedic …

Nitish Kishor | 10 September 2026

Nutriband (NASDAQ: NTRB): The AVERSA Abuse-Deterrent Patch Platform

Nutriband (SEC CIK 1676047) is a pharmaceutical company focused on transdermal and topical products. Its centerpiece is the AVERSA abuse-deterrent transdermal technology, designed to be incorporated into patches - most prominently an abuse-deterrent fentanyl patch - to help deter misuse, diversion and accidental exposure. …

Nitish Kishor | 10 September 2026

PharmaCyte Biotech (NASDAQ: PMCB): The Gap Between Market Value and Cash Position

Headquartered in Las Vegas, Nevada, PharmaCyte Biotech built its early identity around "Cell-in-a-Box," a live-cell encapsulation technology once positioned for pancreatic cancer and other indications. In recent years the company has shifted decisively away from clinical spending and toward what it frames as tactical …

Nitish Kishor | 10 September 2026

Emergent BioSolutions (NYSE: EBS): Government Contracts Versus NARCAN Pricing Pressure

Emergent BioSolutions is a life-sciences company built around public-health preparedness. Its portfolio spans the CYFENDUS and BioThrax anthrax vaccines, the ACAM2000 smallpox and mpox vaccine, botulism antitoxin (BAT), and the over-the-counter NARCAN naloxone nasal spray used to reverse opioid overdoses. Much of its revenue …

Nitish Kishor | 10 September 2026

Cardio Diagnostics Holdings (NASDAQ: CDIO): Bringing Lab Processing In-House

Cardio Diagnostics is a precision-cardiovascular-medicine company that combines epigenetics, genetics and artificial intelligence, using DNA-methylation biomarkers andMachine Learningto assess and detect coronary heart disease. Its core products are the Epi+Gen CHD risk-assessment test and the PrecisionCHD detection test, alongside its HeartRisk and CardioInnovate360 offerings. …

Nitish Kishor | 10 September 2026

Bolt Biotherapeutics (NASDAQ: BOLT): Awaiting BDC-4182's First Clinical Readout

Bolt Biotherapeutics develops cancer immunotherapies built on its Boltbody Immune-Stimulating Antibody Conjugate, or ISAC, platform, which pairs tumor-targeting antibodies with immune-activating payloads. Its lead candidate, BDC-4182, is a next-generation ISAC targeting claudin 18.2 for gastric and gastroesophageal junction cancers, and it is advancing through …

Nitish Kishor | 10 September 2026

Decoy Therapeutics (NASDAQ: DCOY): Building Broad-Spectrum Antivirals via IMP3ACT

Decoy Therapeutics develops AI-designed peptide-conjugate therapeutics through its IMP3ACT platform, which it uses to create what it calls Designable Multi-Antivirals, or D-MAVs, single drugs engineered to work across multiple viruses rather than one at a time. The company says it targets more than 250 …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…